Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Erlotinib
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Heterotransplant
22%
Molecular Determinants
22%
Signal Transduction Pathway
22%
Tumor Response
22%
Tumor
22%
Nude Mice
22%
Stable Disease
22%
Lung Tumor
22%
Molecular Parameters
11%
Epithelial Malignancies
11%
Clinically Significant
11%
Growth Factor Receptor Tyrosine Kinase
11%
Resectable Lung Cancer
11%
Human Non-small Cell Lung Cancer
11%
Toxicity Profile
11%
Tumor Progression
11%
Selective Inhibitor
11%
Chemoresistant
11%
High Probability
11%
Antitumor Activity
11%
Genetic Similarity
11%
Mathematical Algorithm
11%
Primary Tumor
11%
Disease Progression
11%
Epidermal Growth Factor
11%
Clinical Parameters
11%
Predictive Value
11%
Tarceva
11%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
11%
Specific Aims
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Erlotinib
100%
Neoplasm
40%
Epidermal Growth Factor Receptor
20%
Nude Mouse
20%
Tumor Growth
10%
Primary Tumor
10%
Disease Exacerbation
10%
Clinical Study
10%
Antitumor Activity
10%
Epidermal Growth Factor
10%
Diseases
10%
Biochemistry, Genetics and Molecular Biology
Erlotinib
100%
Nude Mouse
22%
Epidermal Growth Factor Receptor
22%
Signal Transduction
22%
Tumor Progression
11%
Epidermal Growth Factor
11%
Genetic Similarity
11%
Clinical Study
11%
Antineoplastic Activity
11%